CMPX ▼ -13.2% - Compass Therapeutics, Inc. $CMPX - Compass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA Feedback Compass Therapeutics shares fell 13.2% following a regulatory update on its tovecimig program in biliary tract cancer after receiving feedback from the FDA. The company's disclosure of FDA guidance on the development program prompted the significant intraday decline. 22-SEP-2026 08:30 AM ET